[Asia Economy Reporter Chunhee Lee] Engchem Life Sciences has obtained a domestic patent for a diabetes treatment substance applying the new drug development material 'EC-18 (Modedipimod)'.
Engchem Life Sciences is currently developing EC-18, a lipid-based new drug. The company explained that EC-18 protects beta cells in acute diabetes caused by drug-induced beta cell destruction, thereby enhancing therapeutic efficacy.
Diabetes is divided into type 1 and type 2. Among them, EC-18 is used as a treatment for type 1 diabetes, an 'insulin-dependent diabetes' caused by insufficient insulin production in the body.
An Engchem Life Sciences official stated, "We have completed PCT international application and US patent application, and the examination is currently underway," adding, "It is expected that global pharmaceutical companies will accelerate technology licensing negotiations through obtaining overseas patents."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
